Last reviewed · How we verify
NCT05482529
Integrative Omics Analysis for Colorectal Cancer and Metastasis
trial testing Integrative omics in Colorectal Cancer in 20 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | fan li |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 August 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Integrative omics
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
fan li — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Translational Bioinformatics Applied to the Study of Complex Diseases.
Casotti MC, Meira DD, Alves LNR, Bessa BGO, et al · · 2023 · cited 12× · PMID 36833346 · DOI 10.3390/genes14020419
Verify or expand the search:
- PubMed search for NCT05482529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other fan li trials
Trials by the same sponsor.
- NCT06718543 — Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT06573424 — Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC · completed
- NCT06225609 — No Stoma VS Ghost Stoma in Patients Undergoing Total Mesorectal Excision for Rectal Cancer · NA · not yet recruiting
- NCT05833672 — Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers · Phase 2 · unknown
- NCT05985239 — Virtual Ileostomy Versus Diverting Ileostomy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05482529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by fan li
- Last refreshed: 1 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05482529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing